Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment

NEJM Evid. 2023 Apr;2(4):EVIDoa2300018. doi: 10.1056/EVIDoa2300018. Epub 2023 Mar 11.

Abstract

Outcomes after Localized Prostate Cancer TreatmentDonovan et al. present the long-term patient-reported outcomes of 1643 randomly assigned participants in the ProtecT (Prostate Testing for Cancer and Treatment) trial. Functional and quality-of-life impacts of prostatectomy, radiotherapy with neoadjuvant androgen deprivation, and active monitoring are described. Over the trial period from 7 to 12 years, generic quality-of-life scores were similar among all groups, with varying degrees of impact on urinary leakage, sexual function, and fecal leakage depending on the treatment group.

MeSH terms

  • Androgen Antagonists
  • Humans
  • Male
  • Patient Reported Outcome Measures
  • Prostatic Neoplasms* / radiotherapy
  • Quality of Life
  • Treatment Outcome

Substances

  • Androgen Antagonists